Kodiak Sciences Misses Q1 Earnings Expectations

Biotech firm reports $0.02 EPS shortfall in latest quarterly results.

Apr. 1, 2026 at 2:18am

Got story updates? Submit your updates here. ›

Kodiak Sciences (NASDAQ:KOD), a clinical-stage biopharmaceutical company focused on retinal disease therapies, reported its first quarter 2026 earnings results on Tuesday. The company reported earnings per share of ($1.04), missing the consensus analyst estimate of ($1.02) by $0.02.

Why it matters

Kodiak Sciences is a closely watched biotech firm developing novel treatments for wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and other serious eye conditions. The company's stock price has been volatile as investors track its pipeline progress, so any earnings misses can impact market sentiment.

The details

Kodiak Sciences reported a loss of $1.04 per share for the first quarter, compared to the average analyst estimate of a $1.02 per share loss. The company's shares traded up 13.3% on the day, closing at $38.12, despite the earnings miss.

  • Kodiak Sciences reported its Q1 2026 earnings results on Tuesday, April 1, 2026.

The players

Kodiak Sciences

A clinical-stage biopharmaceutical company headquartered in Palo Alto, California that focuses on the discovery and development of novel therapies for retinal diseases.

Got photos? Submit your photos here. ›

The takeaway

While Kodiak Sciences missed earnings expectations, the company's stock still saw a significant jump on the day as investors remain optimistic about its pipeline of retinal disease treatments. The biotech firm will need to demonstrate continued progress in its clinical trials to maintain market confidence.